About Ocugen
Ocugen is a company based in Aurora (United States) founded in 2013.. The company has 95 employees as of December 31, 2024. Ocugen offers products and services including Gene Therapies, Vaccines, and Cell Therapies. Ocugen operates in a competitive market with competitors including Adaptive Biotechnologies, Moderna, Kriya Therapeutics, Annexon and Generate Biomedicines, among others.
- Headquarter Aurora, United States
- Employees 95 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Ocugen, Inc.
-
Annual Revenue
$4.05 M-32.82as on Dec 31, 2024
-
Net Profit
$-54.05 M14.31as on Dec 31, 2024
-
EBITDA
$-52.79 M18.57as on Dec 31, 2024
-
Latest Funding Round
$14.28 M (USD), Post-IPO
May 07, 2020
- Investors
-
Employee Count
95
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Ocugen
Ocugen is a publicly listed company on the NASDAQ with ticker symbol OCGN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Ocugen
Ocugen offers a comprehensive portfolio of products and services, including Gene Therapies, Vaccines, and Cell Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treats inherited retinal diseases like retinitis pigmentosa
Develops mucosal vaccines for infectious diseases
Addresses orthopedic diseases through regenerative approaches
Unlock access to complete
Unlock access to complete
Funding Insights of Ocugen
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $14.3M
-
First Round
First Round
(15 May 2015)
- Investors Count 6
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2020 | Amount | Post-IPO - Ocugen | Valuation |
investors |
|
| Aug, 2019 | Amount | Post-IPO - Ocugen | Valuation |
investors |
|
| Nov, 2018 | Amount | Post-IPO - Ocugen | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ocugen
Ocugen has secured backing from 6 investors, including institutional and angel investors. Prominent investors backing the company include Colorado Office of Economic Development and International Trade, Lancaster Group and Abdi Ibrahim. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides financial advisory services, including planning, analysis, and wealth management.
|
Founded Year | Domain | Location | |
|
Economic development and international trade are facilitated for Colorado businesses.
|
Founded Year | Domain | Location | |
|
AI
Abdi Ibrahim |
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ocugen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Ocugen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ocugen Comparisons
Competitors of Ocugen
Ocugen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Biotechnologies, Moderna, Kriya Therapeutics, Annexon and Generate Biomedicines, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| domain | founded_year | HQ Location |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ocugen
Frequently Asked Questions about Ocugen
When was Ocugen founded?
Ocugen was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Where is Ocugen located?
Ocugen is headquartered in Aurora, United States. It is registered at Aurora, Colorado, United States.
How many employees does Ocugen have?
As of Dec 31, 2024, the latest employee count at Ocugen is 95.
What is the annual revenue of Ocugen?
Annual revenue of Ocugen is $4.05M as on Dec 31, 2024.
What does Ocugen do?
Founded in 2013 and based in Aurora, United States, Ocugen operates in the biotechnology sector, focusing on protein therapeutics for eye diseases. Treatments are advanced for conditions such as ocular graft versus host disease, retinitis pigmentosa, geographic atrophy, wet age-related macular degeneration, and diabetic retinopathy. Key products include OCU400 for retinal degeneration, OCU410 for dry age-related macular degeneration, and OCU200 for diabetic macular edema and retinopathy.
Who are the top competitors of Ocugen?
Ocugen's top competitors include Moderna, Adaptive Biotechnologies and Annexon.
What products or services does Ocugen offer?
Ocugen offers Gene Therapies, Vaccines, and Cell Therapies.
Is Ocugen publicly traded?
Yes, Ocugen is publicly traded on NASDAQ under the ticker symbol OCGN.
Who are Ocugen's investors?
Ocugen has 6 investors. Key investors include Colorado Office of Economic Development and International Trade, Lancaster Group, Abdi Ibrahim, Frank Leo, and John Zhang.
What is Ocugen's ticker symbol?
The ticker symbol of Ocugen is OCGN on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.